Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Last Hour:
Last 24 Hours:

TheraLase Technologies’ latest research on anti-cancer compounds to be published

Thursday, April 6, 2017 12:09
% of readers think this story is Fact. Add your two cents.

(Before It's News)

TheraLase Technologies Inc (CVE:TLT, OTCMKTS:TLTFF) and its technology have been further boosted as it’s been shown its latest  generation of anti-cancer compounds may be effective in beating cancer.

The biotech’s latest research on its compounds based on the metal Osmium (OS) has been accepted for publication in Photochemistry and Photobiology -  the official journal of the American Society of Photobiology.

Theralase’s photo dynamic compounds (PDCs) are able to localize to cancer cells, and then when laser light is activated, effectively destroy them.

As reported this week, its lead compound  TLD-1433, is based on the metal ruthenium (Ru).

It is currently under clinical investigation in a phase Ib clinical study for non-muscle invasive bladder cancer (NMIBC).

These new compounds can be activated from ultraviolet (UV) to near infrared (NIR) light, allowing for tissue penetrations from microns up to centimetres.

This new class of  Osmium based compounds also have a strong resistance to photobleaching (ability to remain active in tissue until the cancer cells of interest have been destroyed).

This allows for high-energy, repeated laser irradiations of large tumour volumes to systematically destroy cancerous tumours section by section, while minimizing effects to nearby healthy tissue, Theralase said.

Studies in the Petri dish have shown that these Os PSs have longer wavelength activation and efficacy in red and NIR light, in both normoxic (normal oxygen) and hypoxic (low oxygen) conditions, making them highly suitable for destruction of solid core cancer tumours.

Theralase chief executive and president Roger Dumoulin-White said: Theralase prides itself on combining the immense knowledge and understanding of all of its multidisciplined teams and partners to research and develop PDCs, and the laser systems that activate them, in the quest to destroy a wide range of cancerous tumours.”

Story by ProactiveInvestors


Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.